Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rocket Pharmaceuticals (RCKT) Shares Outstanding (Weighted Average) (2016 - 2025)

Rocket Pharmaceuticals' Shares Outstanding (Weighted Average) history spans 10 years, with the latest figure at $111.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 17.21% year-over-year to $111.1 million; the TTM value through Dec 2025 reached $111.1 million, up 17.21%, while the annual FY2025 figure was $111.1 million, 17.21% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $111.1 million at Rocket Pharmaceuticals, roughly flat from $111.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $111.6 million in Q3 2025 and bottomed at $61.6 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $80.7 million (2023), against an average of $83.0 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) grew 3.74% in 2022 before it rose 23.27% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $63.2 million in 2021, then grew by 7.77% to $68.1 million in 2022, then grew by 23.27% to $84.0 million in 2023, then rose by 12.85% to $94.8 million in 2024, then grew by 17.21% to $111.1 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Shares Outstanding (Weighted Average) are $111.1 million (Q4 2025), $111.6 million (Q3 2025), and $110.6 million (Q2 2025).